PKCα is a Potentially Useful Marker for Planning Individualized Radiotherapy for Nasopharyngeal Carcinoma

References

• Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387:1012–1024. doi:10.1016/S0140-6736(15)00055-026321262
   PubMed Web of Science ®Google Scholar
• Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041–2054. doi:10.1016/S0140-6736(05)66698-615950718
   PubMed Web of Science ®Google Scholar
• Tan LLY, Chua MLK. Discovering biomarkers of radioresistance in a radiosensitive cancer: a clinical paradox in nasopharyngeal carcinoma. Ann Transl Med. 2020;8:1284. doi:10.21037/atm-20-540533209864
   PubMed Web of Science ®Google Scholar
• Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol. 2010;11:103–112. doi:10.1038/nrm284720094051
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang Y, Duan Y, et al. PKCα promotes local advancement via its dual roles in nasopharyngeal carcinoma. Acta Otolaryngol. 2017;137:662–667. doi:10.1080/00016489.2016.126919528084179
   PubMed Web of Science ®Google Scholar
• Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a Phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17:1509–1520. doi:10.1016/S1470-2045(16)30410-727686945
   PubMed Web of Science ®Google Scholar
• Lu J, Tang M, Li H, et al. EBV-LMP1 suppresses the DNA damage response through DNA-PK/AMPK signaling to promote radioresistance in nasopharyngeal carcinoma. Cancer Lett. 2016;380:191–200.27255972
   PubMed Web of Science ®Google Scholar
• Hou Y, Zhu Q, Li Z, et al. The FOXM1-ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells. Cell Death Dis. 2017;8:e2659. doi:10.1038/cddis.2017.5328277541
   PubMed Web of Science ®Google Scholar
• He JJ, Li Z, Rong ZX, et al. m(6)A Reader YTHDC2 promotes radiotherapy resistance of nasopharyngeal carcinoma via activating IGF1R/AKT/S6 signaling axis. Front Oncol. 2020;10:1166. doi:10.3389/fonc.2020.0116632850334
   PubMed Web of Science ®Google Scholar
• Li G, Liu Y, Su Z, et al. MicroRNA-324-3p regulates nasopharyngeal carcinoma radioresistance by directly targeting WNT2B. Eur J Cancer. 2013;49:2596–2607. doi:10.1016/j.ejca.2013.03.00123583221
   PubMed Web of Science ®Google Scholar
• Fu S, Li Z, Xiao L, et al. Glutamine synthetase promotes radiation resistance via facilitating nucleotide metabolism and subsequent DNA damage repair. Cell Rep. 2019;28:1136–1143.e1134. doi:10.1016/j.celrep.2019.07.00231365859
   PubMed Web of Science ®Google Scholar
• Tang J, Bouyer P, Mykoniatis A, Buschmann M, Matlin KS, Matthews JB. Activated PKC{delta} and PKC{epsilon} inhibit epithelial chloride secretion response to cAMP via inducing internalization of the Na+-K+-2Cl- cotransporter NKCC1. J Biol Chem. 2010;285:34072–34085. doi:10.1074/jbc.M110.13738020732874
   PubMed Web of Science ®Google Scholar
• Zhang L, Xie B, Qiu Y, et al. Rab25-mediated EGFR recycling causes tumor acquired radioresistance. iScience. 2020;23:100997. doi:10.1016/j.isci.2020.10099732252020
   PubMed Web of Science ®Google Scholar
• Rahimova N, Cooke M, Zhang S, Baker MJ, Kazanietz MG. The PKC universe keeps expanding: from cancer initiation to metastasis. Adv Biol Regul. 2020;78:100755. doi:10.1016/j.jbior.2020.10075533017725
   PubMedGoogle Scholar
• Antal CE, Hudson AM, Kang E, et al. Cancer-associated protein kinase C mutations reveal kinase’s role as tumor suppressor. Cell. 2015;160:489–502. doi:10.1016/j.cell.2015.01.00125619690
   PubMed Web of Science ®Google Scholar
• Parker PJ, Brown SJ, Calleja V, Chakravarty P, Cobbaut M. Equivocal, explicit and emergent actions of PKC isoforms in cancer. Nat Rev Cancer. 2021;21:51–63. doi:10.1038/s41568-020-00310-433177705
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang T, Chang X, et al. Targeting Opsin4/Melanopsin with a novel small molecule suppresses PKC/RAF/MEK/ERK signaling and inhibits lung adenocarcinoma progression. Mol Cancer Res. 2020;18:1028–1038. doi:10.1158/1541-7786.MCR-19-112032269074
   PubMed Web of Science ®Google Scholar
• Deka SJ, Trivedi V. Potentials of PKC in cancer progression and anticancer drug development. Curr Drug Discov Technol. 2019;16:135–147. doi:10.2174/157016381566618021911361429468974
   PubMedGoogle Scholar
• Lau WM, Teng E, Huang KK, et al. Acquired resistance to FGFR inhibitor in diffuse-type gastric cancer through an AKT-independent PKC-mediated phosphorylation of GSK3β. Mol Cancer Ther. 2018;17:232–242. doi:10.1158/1535-7163.MCT-17-036728978722
   PubMed Web of Science ®Google Scholar
• Bluwstein A, Kumar N, Léger K, et al. PKC signaling prevents irradiation-induced apoptosis of primary human fibroblasts. Cell Death Dis. 2013;4:e498. doi:10.1038/cddis.2013.1523412390
   PubMed Web of Science ®Google Scholar
• Scott JG, Berglund A, Schell MJ, et al. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017;18:202–211. doi:10.1016/S1470-2045(16)30648-927993569
   PubMed Web of Science ®Google Scholar
• Domínguez-García S, Geribaldi-Doldán N, Gómez-Oliva R. A novel PKC activating molecule promotes neuroblast differentiation and delivery of newborn neurons in brain injuries. Cell Death Dis. 2020;11:262. doi:10.1038/s41419-020-2453-932321920
   PubMed Web of Science ®Google Scholar
• Zhao H, Li M, Ouyang Q, Lin G, Hu L. VEGF promotes endothelial cell differentiation from human embryonic stem cells mainly through PKC-ɛ/η pathway. Stem Cells Dev. 2020;29:90–99. doi:10.1089/scd.2019.017231752619
   PubMed Web of Science ®Google Scholar
• Nakura A, Higuchi C, Yoshida K, Yoshikawa H. PKCα suppresses osteoblastic differentiation. Bone. 2011;48:476–484. doi:10.1016/j.bone.2010.09.23820951242
   PubMed Web of Science ®Google Scholar